Thousand Oaks, CA, United States of America

Jennitte LeAnn Stevens

This inventor holds 10 USPTO granted patents and 14 published patent applications and 8 EPO patents. Top assignees: Amgen Inc., Xencor, Inc.. Active years: 2017-2026.

USPTO Granted Patents = 10 (Patent Applications = 14)

% Patents Active = 90.0

EPO Patents = 8 (Patent Applications = 14)

Average Co-Inventor Count = 5.4

ph-index = 2

Forward Citations = 8(Granted Patents)

Location History:

Ventura, CA (US) (2017)
Thousand Oaks, CA (US) (2019 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12709730 - DATA-DRIVEN PREDICTIVE MODELING FOR CELL LINE SELECTION IN BIOPHARMACEUTICAL PRODUCTION (2026-08-18),

2. 12570966 - MUTATED PIGGYBAC TRANSPOSASE (2026-03-10),

3. 12570734 - C-TERMINAL ANTI-SCLEROSTIN ANTIBODY VARIANTS (2026-03-10),

4. 11858983 - C-terminal anti-sclerostin antibody variants (2024-01-02),

5. 11530274 - Anti-STEAP1 antigen-binding protein (2022-12-20),

6. 11466079 - C-terminal antibody variants (2022-10-11),

7. 11248052 - Antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor (2022-02-15),

8. 11149078 - Variants of tissue inhibitor or metalloprotienase type three (TIMP-3), compositions and methods (2021-10-19),

9. 10202616 - Promoter and regulatory elements for improved expression of heterologous genes in host cells (2019-02-12),

10. 9574002 - Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor (2017-02-21),

Title: Jennitte LeAnn Stevens: Innovator in Antibody Research

Introduction

Jennitte LeAnn Stevens is a prominent inventor based in Thousand Oaks, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of innovative antibody therapies. With a total of 10 patents to her name, her work has had a substantial impact on medical research and treatment options.

Latest Patents

Among her latest patents are the "C-terminal anti-sclerostin antibody variants," which relate to anti-sclerostin antibodies featuring C-terminal modifications and compositions that include such antibodies. Another notable patent is the "Anti-STEAP1 antigen-binding protein," which provides novel antigen-binding proteins that specifically bind to STEAP1, along with methods for their use.

Career Highlights

Throughout her career, Jennitte has worked with leading companies in the biotechnology sector, including Amgen Inc. and Xencor, Inc. Her expertise in antibody development has positioned her as a key player in advancing therapeutic solutions.

Collaborations

Jennitte has collaborated with esteemed colleagues such as Mark E. Daris and Yang Li, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Jennitte LeAnn Stevens continues to be a driving force in the field of antibody research, with her inventions paving the way for new therapeutic approaches. Her dedication to innovation exemplifies the spirit of scientific advancement.